Medical resource use and costs associated with chylomicronemia

References

• Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1992;37:249-73
   PubMedGoogle Scholar
• Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007;357:1009-17
   PubMed Web of Science ®Google Scholar
• Benlian P, De Gennes JL, Foubert L, et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996;335:848-54
   PubMed Web of Science ®Google Scholar
• Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res 2011;52:189-206
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009;169:572-8
   PubMedGoogle Scholar
• Bathnagar D. Hypertriglyceridemia. In: Betteridge DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in health and disease. London: Arnold Publishers and Oxford University Press, 1999. p 737-53
   Google Scholar
• O'Brien T, Dinneen SF, O'Brien PC, et al. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993;68:860-6
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Schrott HG. The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. Trans Assoc Am Physicians 1973;86:245-54
   PubMedGoogle Scholar
• Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994;78:117-41
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apo CII deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th edn. New York, NY: McGraw-Hill, 2001. p 2789-16
   Google Scholar
• Tremblay K, Methot J, Brisson D, et al. Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J Clin Lipidol 2011;5:37-44
   PubMed Web of Science ®Google Scholar
• Fung MA, Frohlich JJ. Common problems in the management of hypertriglyceridemia. CMAJ 2002;167:1261-6
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Bierman EL. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am 1982;66:455-68
   PubMed Web of Science ®Google Scholar
• Christian JB, Bourgeois N, Snipes R, et al. Prevalence of severe (500 to 2000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol 2011;107:891-7
   PubMed Web of Science ®Google Scholar
• Brisson D, Methot J, Tremblay K, et al. Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. Pharmacogenet Genomics 2010;20:742-7
   PubMed Web of Science ®Google Scholar
• Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 1998;27:551-67, viii
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9
   PubMed Web of Science ®Google Scholar
• Okosun IS, Chandra KM, Boev A, et al. Abdominal adiposity in U.S. adults: prevalence and trends, 1960-2000. Prev Med 2004;39:197-206
   PubMed Web of Science ®Google Scholar
• Golden SH, Robinson KA, Saldanha I, et al. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009;94:1853-78
   PubMed Web of Science ®Google Scholar
• Thomson Reuters MarketScan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases. Ann Arbor, MI: Thomson Reuters (Healthcare) Inc.; 2010
   Google Scholar
• The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). Hyattsville, MD (NCHS) and Baltimore, MD (CMS): The National Center for Health Statistics (NCHS) and the Centers for Medicare and Medicaid Services, 2010
   Google Scholar
• Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation 1965;31:321-7
   PubMed Web of Science ®Google Scholar
• Rice J. Mathematical statistics and data analysis. 2nd edn. Belmont, CA: Duxbury Press, 1995. p 492-4
   Google Scholar
• Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956. p 75-83
   Google Scholar
• Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet 2008;371:143-52
   PubMed Web of Science ®Google Scholar
• SAS Institute Inc. SAS® software, Version 9.2 for Microsoft® Windows XP. Copyright©. Cary, NC: SAS Institute Inc., 2008
   Google Scholar
• Balu S, Thomas J, 3rd. Incremental expenditure of treating hypertension in the United States. Am J Hypertens 2006;19:810-6; discussion 817
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596-615
   Google Scholar
• Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010;11:55-60
   PubMed Web of Science ®Google Scholar
• Frey CF, Zhou H, Harvey DJ, et al. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006;33:336-44
   PubMed Web of Science ®Google Scholar
• Christian JB, Arondekar B, Buysman EK, et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol 2012;6:450-61
   PubMed Web of Science ®Google Scholar
• Fagenholz PJ, Fernandez-del Castillo C, Harris NS, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas 2007;35:302-7
   PubMed Web of Science ®Google Scholar
• Gaudet D, Gagne C. La morbidité économique des dyslipidémies familiales au Québec. Les actualités du cœur 1997;2:12
   Google Scholar